These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 72132)

  • 1. Mortality of patients with Parkinson's disease treated with levodopa.
    Marttila RJ; Rinne UK; Siirtola T; Sonninen V
    J Neurol; 1977 Oct; 216(3):147-53. PubMed ID: 72132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa treatment of Parkinson's syndrome: past and future.
    Pletscher A
    Adv Neurol; 1990; 53():469-73. PubMed ID: 2239486
    [No Abstract]   [Full Text] [Related]  

  • 3. [L-dopa + peripheral decarboxylase antagonist].
    Wiesel FA
    Lakartidningen; 1975 Oct; 72(43):4173. PubMed ID: 1177632
    [No Abstract]   [Full Text] [Related]  

  • 4. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
    BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J
    Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
    [No Abstract]   [Full Text] [Related]  

  • 6. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
    Campanella G; Pennetta R
    Acta Neurol (Napoli); 1974; 29(3):252-63. PubMed ID: 4417098
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
    Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
    Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of Parkinson's syndromes by a combination of levodopa with decarboxylase inhibitors].
    Hanzal F
    Cesk Neurol Neurochir; 1975 Dec; 38(6):327-32. PubMed ID: 1192544
    [No Abstract]   [Full Text] [Related]  

  • 9. [Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Nervenarzt; 1977 Apr; 48(4):205-10. PubMed ID: 404579
    [No Abstract]   [Full Text] [Related]  

  • 10. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.
    Uitti RJ; Ahlskog JE; Maraganore DM; Muenter MD; Atkinson EJ; Cha RH; O'Brien PC
    Neurology; 1993 Oct; 43(10):1918-26. PubMed ID: 8413948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response variations in the treatment of Parkinson's disease.
    de Jong GJ; Meerwaldt JD
    Neurology; 1984 Nov; 34(11):1507-9. PubMed ID: 6493504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of levodopa therapy in idiopathic Parkinson's disease.
    Gauthier S; Gauthier L
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):452-4. PubMed ID: 3676919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 15. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
    Fischer PA; Schneider E; Jacobi P; Maxion H
    Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206
    [No Abstract]   [Full Text] [Related]  

  • 16. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900
    [No Abstract]   [Full Text] [Related]  

  • 17. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
    Roberts JW; Cora-Locatelli G; Bravi D; Amantea MA; Mouradian MM; Chase TN
    Neurology; 1993 Dec; 43(12):2685-8. PubMed ID: 8255478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brocresine in Parkinson's disease. Action of a peripheral and central decarboxylase inhibitor in potentiating levodopa.
    Howse PM; Matthews WB
    J Neurol Neurosurg Psychiatry; 1973 Feb; 36(1):27-9. PubMed ID: 4570903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors that influence the occurrence of response variations in Parkinson's disease.
    de Jong GJ; Meerwaldt JD; Schmitz PI
    Ann Neurol; 1987 Jul; 22(1):4-7. PubMed ID: 3631919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Citicoline in the treatment of Parkinson's disease.
    Eberhardt R; Birbamer G; Gerstenbrand F; Rainer E; Traegner H
    Clin Ther; 1990; 12(6):489-95. PubMed ID: 2289218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.